Cargando…
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study
BACKGROUND: Inhibition of the epithelial sodium channel (ENaC) in cystic fibrosis (CF) airways provides a mutation-agnostic approach that could improve mucociliary clearance in all CF patients. BI 1265162 is an ENaC inhibitor with demonstrated pre-clinical efficacy and safety already demonstrated in...
Autores principales: | Goss, Christopher H., Fajac, Isabelle, Jain, Raksha, Seibold, Wolfgang, Gupta, Abhya, Hsu, Ming-Chi, Sutharsan, Sivagurunathan, Davies, Jane C., Mall, Marcus A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850685/ https://www.ncbi.nlm.nih.gov/pubmed/34385272 http://dx.doi.org/10.1183/13993003.00746-2021 |
Ejemplares similares
-
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF(TM) 1
por: Goss, Christopher H., et al.
Publicado: (2020) -
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
por: Nickolaus, Peter, et al.
Publicado: (2020) -
First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers
por: Mackie, Alison, et al.
Publicado: (2021) -
Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?
por: Strandvik, Birgitta
Publicado: (2021) -
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
por: Mall, Marcus A.
Publicado: (2020)